按年龄和风险状态常规年度流感疫苗接种的成本效果
该研究构建州转换模拟模型,比较美国按年龄和风险状态分层的假设队列中流感疫苗接种与不接种的健康和经济结局,采用社会视角和医疗部门视角及一年时间范围。结果显示,除18-49岁非高危成人外,所有年龄和风险组的增量成本效果比均低于每质量调整生命年95,000美元。
要点
- 除18-49岁非高危成人外,所有年龄和风险组的ICER低于每QALY 95,000美元。
- 50岁及以上流感相关并发症较高风险成人接种具有成本节约性。
- 65岁及以上老年人疫苗接种在疫苗有效性低至4%时ICER仍低于每QALY 100,000美元。
核心结论
- 流感疫苗接种的成本效果因年龄和风险状态而异,除非高危工作年龄成人外,所有亚组的ICER均低于每QALY 95,000美元。
- 结果对流感患病概率敏感,在某些情景下疫苗接种更为有利。
- 较高风险亚组接种在低疫苗有效性或低循环病毒水平下ICER仍低于每QALY 100,000美元。
研究设计与样本
- 构建州转换模拟模型,估计美国按年龄和风险状态分层的假设队列中流感疫苗接种与不接种的健康和经济结局。
- 模型输入参数来自多个来源,包括美国流感疫苗有效性网络的2009年后疫苗有效性数据。
- 分析采用社会视角和医疗部门视角,时间范围为一年,但永久性结局也被纳入。
主要发现
- 与不接种相比,所有年龄和风险组的ICER均低于每QALY 95,000美元,但18-49岁非高危成人除外(每QALY 194,000美元)。
- 对于50岁及以上流感相关并发症较高风险的成人,接种具有成本节约性。
- 结果对流感患病概率的变化最为敏感。
- 从医疗部门视角分析、排除接种时间成本、在低成本场所接种以及纳入生产力损失可改善疫苗接种的成本效果。
- 敏感性分析显示,对于65岁及以上老年人,在疫苗有效性估计低至4%时,疫苗接种的ICER仍低于每QALY 100,000美元。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The epidemiology of circulating seasonal influenza strains changed following the 2009 pandemic influenza A(H1N1). A universal influenza vaccination recommendation has been implemented and new vaccine types have become available post-2009. The objective of this study was to evaluate the cost-effectiveness of routine annual influenza vaccination in the context of this new evidence. METHODS: A state transition simulation model was constructed to estimate the health and economic outcomes of influenza vaccination compared to no vaccination for hypothetical US cohorts stratified by age and risk status. Model input parameters were derived from multiple sources, including post-2009 vaccine effectiveness data from the US Flu Vaccine Effectiveness Network. The analysis used societal and healthcare sector perspectives and a one-year time horizon, except permanent outcomes were also included. The primary outcome was the incremental cost-effectiveness ratio (ICER) in dollars per quality-adjusted life years (QALYs) gained. RESULTS: Compared to no vaccination, vaccination yielded ICERs lower than $95,000/QALY for all age and risk groups, except for non-high-risk adults 18-49 years ($194,000/QALY). Vaccination was cost-saving for adults ≥50 years at higher risk for influenza-related complications. Results were most sensitive to changes in the probability of influenza illness. Performing the analysis from the healthcare sector perspective, excluding vaccination time costs, delivering vaccinations in lower-cost settings, and including productivity losses improved the cost-effectiveness of vaccination. Sensitivity analysis revealed that vaccination remains below $100,000/QALY for older persons ≥65 years at vaccine effectiveness estimates as low as 4 %. CONCLUSIONS: Cost-effectiveness of influenza vaccination varied by age and risk status and was less than $95,000/QALY for all subgroups, except for non-high-risk working-age adults. Results were sensitive to the probability of influenza illness and vaccination was more favorable under certain scenarios. Vaccination for higher risk subgroups resulted in ICERs below $100,000/QALY even at low levels of vaccine effectiveness or circulating virus.
引用
- Kim DeLuca E, Gebremariam A, Rose A, et al. Cost-effectiveness of routine annual influenza vaccination by age and risk status. Vaccine. 2023. PMID: 37291022. doi:10.1016/j.vaccine.2023.04.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。